Schrodinger launches Bunsen AI co-scientist, raises 2026 drug discovery revenue outlook
The company reported second-quarter ACV growth of 27% and lifted its full-year drug discovery revenue guidance after an Ajax Therapeutics milestone payment.
SEC filing